Literature DB >> 12951586

Reflux, Barrett's oesophagus and adenocarcinoma: burning questions.

Christopher P Wild1, Laura J Hardie.   

Abstract

The incidence of oesophageal adenocarcinoma is increasing rapidly in Western populations. Gastro-oesophageal reflux disease is a strong risk factor for both this tumour and the pre-cancerous lesion Barrett's oesophagus, but the underlying disease mechanisms remain unclear. Developing a better understanding of the aetiology and pathogenesis of Barrett's oesophagus, including the induction of DNA damage and genetic alterations, might provide opportunities for improved management of individuals with this disease. This could include a better rationale for screening and surveillance programmes, as well as targeted intervention strategies.

Entities:  

Mesh:

Year:  2003        PMID: 12951586     DOI: 10.1038/nrc1166

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  70 in total

1.  Plasma and esophageal mucosal levels of vitamin C: role in the pathogenesis and neoplastic progression of Barrett's esophagus.

Authors:  A Fountoulakis; I G Martin; K L M White; M F Dixon; J E Cade; H M Sue-Ling; C P Wild
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

Review 2.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

Review 3.  Risk factors for neoplastic progression in Barrett's esophagus.

Authors:  Elizabeth F Wiseman; Yeng S Ang
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

4.  Acid-induced p16 hypermethylation contributes to development of esophageal adenocarcinoma via activation of NADPH oxidase NOX5-S.

Authors:  Jie Hong; Murray Resnick; Jose Behar; Li Juan Wang; Jack Wands; Ronald A DeLellis; Rhonda F Souza; Stuart J Spechler; Weibiao Cao
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-06-24       Impact factor: 4.052

5.  Deletion at fragile sites is a common and early event in Barrett's esophagus.

Authors:  Lisa A Lai; Rumen Kostadinov; Michael T Barrett; Daniel A Peiffer; Dimitry Pokholok; Robert Odze; Carissa A Sanchez; Carlo C Maley; Brian J Reid; Kevin L Gunderson; Peter S Rabinovitch
Journal:  Mol Cancer Res       Date:  2010-07-20       Impact factor: 5.852

6.  Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis.

Authors:  Sumera Rizvi; Cathrine J Demars; Andrea Comba; Vladimir G Gainullin; Zaheer Rizvi; Luciana L Almada; Kenneth Wang; Gwen Lomberk; Martin E Fernández-Zapico; Navtej S Buttar
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

7.  Role of NADPH oxidase NOX5-S, NF-κB, and DNMT1 in acid-induced p16 hypermethylation in Barrett's cells.

Authors:  Jie Hong; Dan Li; Jack Wands; Rhonda Souza; Weibiao Cao
Journal:  Am J Physiol Cell Physiol       Date:  2013-09-11       Impact factor: 4.249

8.  CDX1 is an important molecular mediator of Barrett's metaplasia.

Authors:  N A C S Wong; J Wilding; S Bartlett; Y Liu; B F Warren; J Piris; N Maynard; R Marshall; W F Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-13       Impact factor: 11.205

9.  Targeting chemokine pathways in esophageal adenocarcinoma.

Authors:  Makardhwaj S Shrivastava; Zulfiqar Hussain; Orsolya Giricz; Niraj Shenoy; Rahul Polineni; Anirban Maitra; Amit Verma
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 10.  History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.

Authors:  Stuart Jon Spechler; Rebecca C Fitzgerald; Ganapathy A Prasad; Kenneth K Wang
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.